Table 1.

Patient demographics and baseline characteristics

Baseline characteristicsVaccinated (n = 14)Screen failure (n = 12)P
Age, y: mean ± SD (median and range)50.5 ± 11.1 (48.6, 33–70)54.5 ± 12.1 (55.0, 33–80)0.38
Gender, n (%)0.99
 Male1 (7.1)0
 Female13 (92.9)12 (100)
Race, n (%)0.99
 White12 (85.7)10 (83.3)
 Black1 (7.1)1 (8.3)
 Unknown1 (7.1)1 (8.3)
Biomarker profile, n (%)
 ER+14 (100)10 (83.3)0.20
 Her-2+3 (21.4)1 (8.3)0.59
 Triple negative0 (0)2 (16.7)0.20
Prior therapy, n (%)
 Chemotherapy9 (64.3)9 (75)0.68
 Endocrine therapy14 (100)10 (83.3)0.20
 Radiation7(50)5 (41.7)0.71
 Surgery12 (85.7)12 (100)0.48
Site of disease, n (%)
 Bone-only8 (57.1)4 (33.3)0.26
 Viscera-only0 (0)2 (16.7)0.20
 Lymph nodes-only1 (7.1)0 (0)0.99
 Multiple sites4 (28.6)7 (58.3)0.23
Screen fails, n (%)
 HLA typing9 (75)
 Withdrew consent2 (16.7)
 Tissue unavailable1 (8.3)